-
Security Type
-
Crowd SAFE
-
Min Investment
-
$250
-
Offering Date
-
January 24, 2023
-
Expected Close Date
-
April 30, 2023
-
Target Raise
-
$25.00K-$1.24M
-
No. Investors
-
31
-
Security Price
-
$1
- Number of Employees
- 18
- Cash
- $1,810,709
- Revenue
- $2,014,066
- Short Term Debt
- $287,110
- Cost of Goods
- $0
- Long Term Debt
- $188,555
- Net Income
- $1,772,158
Company Description
at the intersection of pharmacology,
mental health, and sustainability.
Key Deal Facts
An innovative synthetic biology & cellular agriculture platform
Sustainable, efficient and zero carbon emissions
Backed by the leading biopharma for mental health treatments (Atai)
Specialized scientific team with more than 100 years of combined experience
Generating revenues since 2022 | Targeting profitability by end of Q1 2023*
Prolific patent portfolio with 7 granted and 13 pending patents
Raised more than $11M to date | $5M from Y Combinator
Management Team / Advisory Board Bios
Sher Butt
Founder
Jacob Vogan
Co-founder, Chief Scientific Officer and Board Member
Jim Wade, PhD
Director, Analytical Chemistry
Aaron Cantu, MS
Head of Fermentation and Downstream Processing
Laura Peiffer, PhD
Associate Director, Strain Engineering
Erin Scott, PhD
Associate Director, Microbiology
Tyler Huelsman
Senior Research Associate
Phu Kat Nwe
Scientist I – Strain Engineering
Thanos Karavokiris
VP, Operations
Tiffany Hurd
Business Development Lead
Pamela Vizanko
Sales Director
Stephanie Elliott
Office Manager